Skip to content

Aptima® KIT, BOX 1, REFRIGERATED, ABV, 100T, IVDRecalls & reported problems

Hologic, Inc. · Aptima® BV assay, 100 test, box 1 of 2 (2°C to 8°C box). The Aptima® BV assay is an in vitro nucleic acid amplification test that utilizes real time transcription-mediated amplification (TMA®) for detection and quantitation of ribosomal RNA from bacteria associated with bacterial vaginosis (BV), including Lactobacillus (L. gasseri, L. crispatus, and L. jensenii), Gardnerella vaginalis, and Atopobium vaginae. · Class 2

All models of Aptima (15)

Data updated Oct 18, 2026 from official FDA records · Editorial policy

Adverse event reports
1
Deaths reported
0
Injuries reported
0
Recalls naming it
0

Summary

The FDA's MAUDE database contains 1 adverse event report that list this exact device (DI 15420045512023), received between Jul 22, 2022 and Jul 22, 2022 — classified as 1 malfunction.

The most frequently reported specific device problem is “Imprecise or Erratic Results” (1 report).

Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. What reports can and can't tell you · How this data works · Data updated Oct 18, 2026.

Most reported problems

Device problems

  • Imprecise or Erratic Results1

Patient problems

  • No Clinical Signs, Symptoms or Conditions1

Recent adverse event reports

The 1 most recent of 1 reports, in the reporter's own words as published by the FDA.

  • MalfunctionJul 22, 2022Imprecise or Erratic Results; Imprecise or Erratic Results

    ON (B)(6) 2022, A CUSTOMER REPORTED DISCREPANT RESULTS TO HOLOGIC FOR THE APTIMA BACTERIAL VAGINOSIS (BV) ASSAY FROM, PN ASY-11550 LOT NUMBER 318661. INITIAL RUN RESULTS INDICATE A NEGATIVE BV RESULT. RETEST RESULTS INDICATE A BV POSITIVE RESULT. PER CUSTOMER REQUEST, HOLOGIC REVIEWED THE LOGS AND NOTIFIED CUSTOMER OF POTENTIALLY AFFECTED SAMPLES. THE CUSTOMER RETESTED THE SAMPLES AND IDENTIFIED TWO SAMPLES THAT WERE DISCORDANT. THE CUSTOMER INDICATED THAT THEY CORRECTED THE REPORT FOR THESE SPECIMENS TO BV POSITIVE. THERE IS NO INDICATION THAT AN ADVERSE EVENT OCCURRED (THE PATIENT WAS IMPACTED) DUE TO THE INCORRECT RESULT. REVIEW OF CUSTOMER DATA BY HOLOGIC NOTED THAT PREVIOUS ABV RUNS HAD THE ¿CCE¿ FLAG, WHICH IS A CALIBRATION CHANNEL ERROR. PER AW-20220-001, REV. 001, THE PANTHER/PANTHER FUSION OPERATOR¿S MANUAL INDICATES TO CONTACT HOLOGIC TECHNICAL SUPPORT WHEN THEY RECEIVE THE ¿CCE¿ ERROR CODE. THE ISSUE WAS LIKELY CAUSED BY DEBRIS IN THE RTF. ROOT CAUSE INVESTIGATION IS IN PROCESS.

    Patient problems: No Clinical Signs, Symptoms or Conditions

    MAUDE report 15089973 ↗

Other Assayed external control material for microbiology nucleic acid amplification (NAT) assays devices

All Assayed external control material for microbiology nucleic acid amplification (NAT) assays devices →

Sources and updates

How reports and recalls are matched · Editorial policy · Report an error on this page